Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. News
Matinas BioPharma Holdings, Inc. Quantitative Score

About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Matinas BioPharma Holdings, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Matinas BioPharma Holdings, Inc. Financials
Table Compare
Compare MTNB metrics with: | |||
---|---|---|---|
Earnings & Growth | MTNB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MTNB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MTNB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MTNB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Matinas BioPharma Holdings, Inc. Income
Matinas BioPharma Holdings, Inc. Balance Sheet
Matinas BioPharma Holdings, Inc. Cash Flow
Matinas BioPharma Holdings, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Buy |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Matinas BioPharma Holdings, Inc. Executives
Name | Role |
---|---|
Mr. Jerome D. Jabbour J.D. | Co-Founder, Chief Executive Officer & Chairman |
Mr. Keith A. Kucinski CPA, M.B.A. | Chief Financial Officer |
Mr. Frank Calamusa | Executive Director and Head of Manufacturing & Supply Chain |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Jerome D. Jabbour J.D. | Co-Founder, Chief Executive Officer & Chairman | Male | 1974 | 598K |
Mr. Keith A. Kucinski CPA, M.B.A. | Chief Financial Officer | Male | 1970 | 584.16K |
Mr. Frank Calamusa | Executive Director and Head of Manufacturing & Supply Chain | Male | -- |
Matinas BioPharma Holdings, Inc. Insider Trades
Date | 30 Apr |
Name | NEUGEBOREN EDWARD |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 11600 |
Date | 30 Apr |
Name | Smith Robin L |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 11600 |
Date | 30 Apr |
Name | D An Evelyn |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 11600 |
Date | 30 Apr |
Name | Jabbour Jerome D |
Role | President and CEO |
Transaction | Acquired |
Type | A-Award |
Shares | 70100 |
Date | 30 Apr |
Name | Murphy Keith |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 11600 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
30 Apr | NEUGEBOREN EDWARD | Director | Acquired | A-Award | 11600 |
30 Apr | Smith Robin L | Director | Acquired | A-Award | 11600 |
30 Apr | D An Evelyn | Director | Acquired | A-Award | 11600 |
30 Apr | Jabbour Jerome D | President and CEO | Acquired | A-Award | 70100 |
30 Apr | Murphy Keith | Director | Acquired | A-Award | 11600 |